(Q39001350)

8 September 2017

Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam (English)

1 reference

8 September 2017

1 reference

ChEBI release 2020-05-28

1 reference

1 reference

Patricia A Bradford

8

0 references

author name string

Renu Singh

1

1 reference

8 September 2017

Aryun Kim

2

1 reference

8 September 2017

M Angela Tanudra

3

1 reference

8 September 2017

Jennifer J Harris

4

1 reference

8 September 2017

Robert E McLaughlin

5

1 reference

8 September 2017

Sara Patey

6

1 reference

8 September 2017

John P O'Donnell

7

1 reference

8 September 2017

Ann E Eakin

9

1 reference

8 September 2017

language of work or name

English

0 references

publication date

29 May 2015

1 reference

Journal of Antimicrobial Chemotherapy

8 September 2017

1 reference

8 September 2017

70

1 reference

8 September 2017

9

1 reference

8 September 2017

2618-2626

1 reference

The emerging NDM carbapenemases

8 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV132

Metallo-β-lactamases: a last frontier for β-lactams?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV132

Does broad-spectrum beta-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV132

Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV132

Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV132

Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV132

Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV132

Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV132

Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV132

Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV132

Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV132

Single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV132

Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV132

Animal model pharmacokinetics and pharmacodynamics: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV132

Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV132

Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV132

Pharmacodynamics of TD-1792, a novel glycopeptide-cephalosporin heterodimer antibiotic used against Gram-positive bacteria, in a neutropenic murine thigh model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV132

Use of a predictor panel to evaluate susceptibility test methods proposed for piperacillin-tazobactam

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV132

21 January 2018

Does the dose matter?

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV132

Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV132

Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV132

New β-lactamase inhibitors: a therapeutic renaissance in an MDR world

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV132

Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV132

Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV132

In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV132

The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV132

Novel modeling framework to guide design of optimal dosing strategies for β-lactamase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV132

Optimizing dosage to prevent emergence of resistance - lessons from in vitro models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKV132

21 January 2018

Identifiers

DOI

10.1093/JAC/DKV132

1 reference

8 September 2017

1 reference